Status:
COMPLETED
Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH
Lead Sponsor:
Dong-A ST Co., Ltd.
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This study evaluates the long-term safety of Udenafil in Patient with Pulmonary Arterial Hypertension(PAH). All the patients will receive Udenafil for 1-year(48-weeks).
Detailed Description
Pulmonary arterial Hypertension is characterized by a progressive incerease in pulmonary vascular resistance(PVR) leading to right ventricualar failure. Udenafil inhibits PDE 5, an enzyme that metabo...
Eligibility Criteria
Inclusion
- Patients who completed the initial study(DA8159\_PAH\_II), 12-week, double-blind, placebo-controlled trial
Exclusion
- \-
Key Trial Info
Start Date :
April 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2016
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT02304198
Start Date
April 1 2014
End Date
February 1 2016
Last Update
April 18 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, Gangnam-Gu, Irwon-Dong 50, South Korea, 135-710